More info
Mahima Gulati
Dr Mahima Gula, is a triple board-certified physician: certified in Endocrinology, Diabetes, and Metabolism; as well as Internal Medicine and Board-certified Diplomate of the American Board of Lifestyle Medicine.
She is an Associate Professor, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism at the University of Connecticut School of Medicine, Farmington, Connecticut, as well as adjunct Associate Professor of Internal Medicine at Frank H. NeOer School of Medicine, Quinnipiac University, North Haven, Connecticut.
She founded the service line of Lifestyle Medicine at Middlesex Health, Middletown, Connecticut and served as the medical director of Lifestyle Medicine there until summer 2023. Since moving to University of Connecticut School of Medicine in 2024, she is now directing novel Lifestyle Medicine endocrinology service line including Lifestyle Medicine Shared medical appointments, as well as serving as the chief clinical Lifestyle Medicine Interest Group faculty advisor for medical students and director of the Lifestyle Medicine Residency Curriculum for endocrinology fellows at UConn Health.
She was elected to the Board of Directors at American College of Lifestyle Medicine in November 2022 and currently serves as director-at-large. She was also the founding chair of the Endocrinology member interest group at American College of Lifestyle Medicine, and now serves as its co-chair. She was awarded the prestigious Fellowship of the American College of Lifestyle Medicine in October 2021 and has been a Fellow of the American College of Endocrinology since 2017.
Dr. Gulati has published several journal articles and textbook chapters on both endocrine and lifestyle medicine topics. She coauthored the American College of Lifestyle Medicine’s multidisciplinary comprehensive clinical practice guidelines on “Lifestyle Medicine for type 2 diabetes and prediabetes” and coauthored the American College of Lifestyle Medicine’s expert consensus statement on “Dietary interventions for type 2 diabetes remission” published in 2022.
